RARA CRAFT DATABASE for FDA Medical Devices
PMAP240028

FDA DEVICE FACTS

WiSE® (Wireless Stimulation of the Endocardium Technology) CRT System

EBR Systems, Inc.

Verified FDA Record identity for medical-device development research. This overview uses only fields stated in the FDA Record and is not a Device Description.医療機器開発の調査用に、確認済みの FDA Record の識別情報を示しています。この概要は FDA Record に記載された項目だけによるもので、機器説明ではありません。

DECISION DATEApril 11, 2025PRODUCT CODESEG

Indications for use

The WiSE CRT System is indicated for adult patients who are at least 22 years of age, are indicated for cardiac resynchronization therapy (CRT), have an existing or are eligible for an implanted right ventricular pacing system, and are in one of the following two categories:

• Patients in whom previous coronary sinus (CS) lead implantation was unsuccessful, or where an implanted lead has been turned off, referred to as "previously untreatable";

• Patients with previously implanted pacemakers or Implantable Cardioverter-Defibrillators (ICDs) in whom standard CRT upgrade is not advisable due to known relative contraindications for CS lead or CRT device implantation, referred to as "high risk upgrades".

These categories are defined as follows:

Previously Untreatable: Patients who have a full or partial CRT system and are deemed as 'previously untreatable' for one of the following reasons:

• CS lead implant was attempted but abandoned due any of the following: difficult CS access or anatomy, inadequate lead location, inadequate pacing thresholds, phrenic nerve stimulation (PNS), or other procedural challenges;

• Left ventricular (LV) lead that was implanted but not operational including patients in whom the LV lead is inoperative or programmed off due to improper function such as high threshold, non-capture, PNS, lead failure, lead dislodgement, or suboptimal LV lead location.

High Risk Upgrades: Patients in whom standard CRT upgrade is not advisable due to known relative contraindication to CS lead implant, for example:

• Risk of venous occlusion or lesion precluding implant (e.g., multiple existing leads in situ);

• Risk of pocket infection at co-implanted device site (e.g., co-implant initial placement or battery change within last 12 months);

• Considered high risk for CS implant due to co-morbidities (e.g., history of Ischemic Cardiomyopathy or Ventricular Tachycardia (VT) with risk of epicardial pacing induced VT).

There is insufficient evidence to support the use of the WiSE CRT System in prior CRT non-responders. The safety and effectiveness of the WiSE CRT System has not been established with leadless pacemaker co-implants that utilize conductive communication (e.g., Abbott Aveir).

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: September 2, 2026